213 related articles for article (PubMed ID: 29545428)
1. Metastatic primary pulmonary melanoma successfully treated with checkpoint inhibitors.
Al-Helou G; Temesgen N; Gwizdala J; Ahari J
BMJ Case Rep; 2018 Mar; 2018():. PubMed ID: 29545428
[TBL] [Abstract][Full Text] [Related]
2. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071
[TBL] [Abstract][Full Text] [Related]
3. Complete intracranial response to talimogene laherparepvec (T-Vec), pembrolizumab and whole brain radiotherapy in a patient with melanoma brain metastases refractory to dual checkpoint-inhibition.
Blake Z; Marks DK; Gartrell RD; Hart T; Horton P; Cheng SK; Taback B; Horst BA; Saenger YM
J Immunother Cancer; 2018 Apr; 6(1):25. PubMed ID: 29622046
[TBL] [Abstract][Full Text] [Related]
4. Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasis.
Chorti E; Kanaki T; Zimmer L; Hadaschik E; Ugurel S; Gratsias E; Roesch A; Bonella F; Wessendorf TE; Wälscher J; Theegarten D; Schadendorf D; Livingstone E
Eur J Cancer; 2020 May; 131():18-26. PubMed ID: 32248071
[TBL] [Abstract][Full Text] [Related]
5. Swinging for the Fences: Long-Term Survival With Ipilimumab in Metastatic Melanoma.
Gibney GT; Atkins MB
J Clin Oncol; 2015 Jun; 33(17):1873-7. PubMed ID: 25964248
[TBL] [Abstract][Full Text] [Related]
6. Severe Radiation Necrosis Refractory to Surgical Resection in Patients with Melanoma and Brain Metastases Managed with Ipilimumab/Nivolumab and Brain-Directed Stereotactic Radiation Therapy.
Shi DD; Arnaout O; Bi WL; Buchbinder EI; Cagney DN; Insco ML; Liu D; Schoenfeld JD; Aizer AA
World Neurosurg; 2020 Jul; 139():226-231. PubMed ID: 32330622
[TBL] [Abstract][Full Text] [Related]
7. Acute interstitial nephritis after sequential ipilumumab - nivolumab therapy of metastatic melanoma.
Bottlaender L; Breton AL; de Laforcade L; Dijoud F; Thomas L; Dalle S
J Immunother Cancer; 2017 Jul; 5(1):57. PubMed ID: 28716106
[TBL] [Abstract][Full Text] [Related]
8. Severe thromboembolic phenomenon in the setting of pseudoprogression of melanoma brain metastases in response to combination immunotherapy.
Perez MC; Yu HM; Markowitz J
BMJ Case Rep; 2018 Aug; 2018():. PubMed ID: 30108120
[TBL] [Abstract][Full Text] [Related]
9. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.
Long GV; Atkinson V; Lo S; Sandhu S; Guminski AD; Brown MP; Wilmott JS; Edwards J; Gonzalez M; Scolyer RA; Menzies AM; McArthur GA
Lancet Oncol; 2018 May; 19(5):672-681. PubMed ID: 29602646
[TBL] [Abstract][Full Text] [Related]
10. Intracranial antitumor responses of nivolumab and ipilimumab: a pharmacodynamic and pharmacokinetic perspective, a scoping systematic review.
van Bussel MTJ; Beijnen JH; Brandsma D
BMC Cancer; 2019 May; 19(1):519. PubMed ID: 31146733
[TBL] [Abstract][Full Text] [Related]
11. Investigation of clinical factors associated with longer overall survival in advanced melanoma patients treated with sequential ipilimumab.
Muto Y; Kitano S; Tsutsumida A; Namikawa K; Takahashi A; Nakamura Y; Yamanaka T; Yamamoto N; Yamazaki N
J Dermatol; 2019 Jun; 46(6):498-506. PubMed ID: 30945333
[TBL] [Abstract][Full Text] [Related]
12. The effect of timing of stereotactic radiosurgery treatment of melanoma brain metastases treated with ipilimumab.
Cohen-Inbar O; Shih HH; Xu Z; Schlesinger D; Sheehan JP
J Neurosurg; 2017 Nov; 127(5):1007-1014. PubMed ID: 28059663
[TBL] [Abstract][Full Text] [Related]
13. Long-term survival in metastatic malignant melanoma: ipilimumab followed by vemurafenib in a patient with brain metastasis.
Balakan O; Süner A; Yiğiter R; Balakan T; Sirikçi A; Sevinç A
Intern Med; 2012; 51(19):2819-23. PubMed ID: 23037483
[TBL] [Abstract][Full Text] [Related]
14. Concurrent Radiosurgery and Immune Checkpoint Inhibition: Improving Regional Intracranial Control for Patients With Metastatic Melanoma.
Murphy B; Walker J; Bassale S; Monaco D; Jaboin J; Ciporen J; Taylor M; Dai Kubicky C
Am J Clin Oncol; 2019 Mar; 42(3):253-257. PubMed ID: 30557166
[TBL] [Abstract][Full Text] [Related]
15. Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery.
Mathew M; Tam M; Ott PA; Pavlick AC; Rush SC; Donahue BR; Golfinos JG; Parker EC; Huang PP; Narayana A
Melanoma Res; 2013 Jun; 23(3):191-5. PubMed ID: 23462208
[TBL] [Abstract][Full Text] [Related]
16. Tolerance and outcomes of stereotactic radiosurgery combined with anti-programmed cell death-1 (pembrolizumab) for melanoma brain metastases.
Nardin C; Mateus C; Texier M; Lanoy E; Hibat-Allah S; Ammari S; Robert C; Dhermain F
Melanoma Res; 2018 Apr; 28(2):111-119. PubMed ID: 29356789
[TBL] [Abstract][Full Text] [Related]
17. Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment.
Anderson ES; Postow MA; Wolchok JD; Young RJ; Ballangrud Å; Chan TA; Yamada Y; Beal K
J Immunother Cancer; 2017 Oct; 5(1):76. PubMed ID: 29037215
[TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
Schachter J; Ribas A; Long GV; Arance A; Grob JJ; Mortier L; Daud A; Carlino MS; McNeil C; Lotem M; Larkin J; Lorigan P; Neyns B; Blank C; Petrella TM; Hamid O; Zhou H; Ebbinghaus S; Ibrahim N; Robert C
Lancet; 2017 Oct; 390(10105):1853-1862. PubMed ID: 28822576
[TBL] [Abstract][Full Text] [Related]
19. Fulminant response to combined checkpoint inhibition with ipilimumab plus nivolumab after failure of nivolumab monotherapy in metastatic melanoma.
Ugurel S; Kiecker F; Fröhling S; Wetter A; Bankfalvi A; Sucker A; Zimmer L; Livingstone E; Roesch A; Becker JC; Schadendorf D
Eur J Cancer; 2017 Sep; 83():142-145. PubMed ID: 28735071
[No Abstract] [Full Text] [Related]
20. CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS.
Hodi FS; Oble DA; Drappatz J; Velazquez EF; Ramaiya N; Ramakrishna N; Day AL; Kruse A; Mac Rae S; Hoos A; Mihm M
Nat Clin Pract Oncol; 2008 Sep; 5(9):557-61. PubMed ID: 18665147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
